Prospective, Non Interventional Study to Evaluate the Safety Profile of First- Line Rituximab Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma

Trial Profile

Prospective, Non Interventional Study to Evaluate the Safety Profile of First- Line Rituximab Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 May 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 03 Oct 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
    • 03 Oct 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
    • 27 Apr 2016 Time frame for primary endpoint chnaged from 4 years to 3 years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top